Tempus (NASDAQ: TEM) has agreed to acquire Personalis (NASDAQ: PSNL) in an all-cash transaction valued at $16.25 per share. The acquisition will integrate Personalis' Molecular Residual Disease (MRD) testing capabilities into Tempus' AI-enabled precision oncology platform. Sector: Healthcare Technology / Precision Medicine Key Highlights: 🤝 Tempus to acquire Personalis for $16.25 per share in an all-cash deal 🧬 Integrates Molecular Residual Disease (MRD) testing into Tempus' oncology platform 🤖 Combines Personalis' genomic diagnostics with Tempus' AI and clinical data platform 🎯 Expands capabilities for early cancer detection, treatment monitoring, and recurrence tracking 💊 Strengthens Tempus' precision medicine solutions for healthcare providers and biopharma partners Why It Matters The acquisition enhances Tempus' precision oncology platform by adding advanced MRD testing, enabling more personalized cancer care through AI-driven insights and genomic data. It also strengthens the company's position in the rapidly growing precision medicine and oncology diagnostics market. https://www.thinksabio.com/reports/isr/TEM